Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model

Open access

Abstract

TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20200785

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-SA · PubMed Central
Figure 1. AL002c is a TREM2 agonist. (A) CV- and R47H-derived BMM were cultured for 7 d, harvested, and stained with AL002c (black solid line histograms) or isotype control (gray histograms). This experiment is representative of three independent experiments. (B) 2B4 reporter cell lines expressing hTREM2 CV or hTREM2 R47H were stimulated with grading doses of control IgG or AL002c in solution. EGFP expression was measured by flow cytometry. Data are representative of two independent experiments as mean ± SEM. (C) Human macrophages were cultured for 7 d and stimulated for 48 h with grading doses of IgG or AL002c in solution. Viability was measured by CellTiter Glow. Data are representative of 10 independent experiments as mean ± SD. (D) BMM derived from CV-KO and R47H-KO were cultured for 7 d and stimulated for 96 h with grading doses of IgG or AL002c in solution. Viability was measured by CellTiter Glow. ***, P < 0.001 by two-way ANOVA. Data are presented as mean ± SEM. (E) BMM derived from CV-KO and R47H-KO were stimulated for 15 min with two different concentrations of control IgG or AL002c. Cells were then lysed, immunoprecipitated (IP) with a distinct anti-TREM2 antibody, blotted with anti-phosphotyrosine antibody, stripped, and blotted with anti-DAP12 antibody. For control loading, whole-cell lysates were blotted with anti-actin antibody.
Figure 1. AL002c is a TREM2 agonist. (A) CV- and R47H-derived BMM were cultured for 7 d, harvested, and stained with AL002c (black solid line histograms) or isotype control (gray histograms). This experiment is representative of three independent experiments. (B) 2B4 reporter cell lines expressing hTREM2 CV or hTREM2 R47H were stimulated with grading doses of control IgG or AL002c in solution. EGFP expression was measured by flow cytometry. Data are representative of two independent experiments as mean ± SEM. (C) Human macrophages were cultured for 7 d and stimulated for 48 h with grading doses of IgG or AL002c in solution. Viability was measured by CellTiter Glow. Data are representative of 10 independent experiments as mean ± SD. (D) BMM derived from CV-KO and R47H-KO were cultured for 7 d and stimulated for 96 h with grading doses of IgG or AL002c in solution. Viability was measured by CellTiter Glow. ***, P < 0.001 by two-way ANOVA. Data are presented as mean ± SEM. (E) BMM derived from CV-KO and R47H-KO were stimulated for 15 min with two different concentrations of control IgG or AL002c. Cells were then lysed, immunoprecipitated (IP) with a distinct anti-TREM2 antibody, blotted with anti-phosphotyrosine antibody, stripped, and blotted with anti-DAP12 antibody. For control loading, whole-cell lysates were blotted with anti-actin antibody.CC BY-NC-SA · PubMed Central
Figure S1. AL002c activates hTREM2 signaling and function in vitro. (A) Parental, hTREM2-CV, and -R47H 2B4 reporter cell lines were stimulated with plate-bound phosphatidylcholine. Live cells were gated and tested for EGFP expression. Stimulation of hTREM2-CV, and to a minor extent hTREM2-R47H, induced EGFP. SSC, side scatter; FSC, forward scatter. (B) BW5.147G14 cells expressing hTREM2 (CV) were stimulated with two concentrations of AL002c or control IgG in medium for 6 h, and luciferase expression was measured by adding OneGlo reagent. *, P < 0.05 by unpaired two-tailed t-test. Data are presented as mean ± SEM. (C) Cell viability assay of hTREM2+ macrophages treated with different concentrations of soluble AL002c with intact Fc and mutated Fc (AL002 LALAPS). Data are presented as mean ± SD. (D) WT and hTREM2-Bac-Tg BMM were stimulated for 3 min with control IgG (CTR), anti-mouse TREM2 mAb msAL002, or anti-hTREM2 mAb AL002c, followed by cross-linking with a secondary antibody. Cells were then lysed and immunoprecipitated (IP) with a distinct anti-TREM2 antibody and blotted with anti-phosphotyrosine antibody. For control loading, the membrane was stripped and probed with anti-DAP12 antibody. (E) WT or hTREM2-Bac-Tg mice were injected at day 0 with 3% thioglycolate. At day 3, mice were injected with the AL002c or CTR antibodies. 24 h later, peritoneal cells were collected, immunoprecipitated with anti-TREM2 antibody, and blotted with anti-phosphotyrosine antibody. For control loading, whole-cell lysates were blotted with anti-hTREM2 antibody.
Figure S1. AL002c activates hTREM2 signaling and function in vitro. (A) Parental, hTREM2-CV, and -R47H 2B4 reporter cell lines were stimulated with plate-bound phosphatidylcholine. Live cells were gated and tested for EGFP expression. Stimulation of hTREM2-CV, and to a minor extent hTREM2-R47H, induced EGFP. SSC, side scatter; FSC, forward scatter. (B) BW5.147G14 cells expressing hTREM2 (CV) were stimulated with two concentrations of AL002c or control IgG in medium for 6 h, and luciferase expression was measured by adding OneGlo reagent. *, P < 0.05 by unpaired two-tailed t-test. Data are presented as mean ± SEM. (C) Cell viability assay of hTREM2+ macrophages treated with different concentrations of soluble AL002c with intact Fc and mutated Fc (AL002 LALAPS). Data are presented as mean ± SD. (D) WT and hTREM2-Bac-Tg BMM were stimulated for 3 min with control IgG (CTR), anti-mouse TREM2 mAb msAL002, or anti-hTREM2 mAb AL002c, followed by cross-linking with a secondary antibody. Cells were then lysed and immunoprecipitated (IP) with a distinct anti-TREM2 antibody and blotted with anti-phosphotyrosine antibody. For control loading, the membrane was stripped and probed with anti-DAP12 antibody. (E) WT or hTREM2-Bac-Tg mice were injected at day 0 with 3% thioglycolate. At day 3, mice were injected with the AL002c or CTR antibodies. 24 h later, peritoneal cells were collected, immunoprecipitated with anti-TREM2 antibody, and blotted with anti-phosphotyrosine antibody. For control loading, whole-cell lysates were blotted with anti-hTREM2 antibody.CC BY-NC-SA · PubMed Central
Figure S2. AL002 pharmacokinetics. (A) Timeline of pharmacokinetics (PK) study of AL002 in TREM2-Bac-Tg mice. A single dose of AL002 was administered on day 0 at 5, 20, and 60 mg/kg. Different mouse cohorts were sacrificed on days 1, 2, 4, 8, 14, and 21, and plasma and brain samples were collected for measurement of antibody levels. (B) AL002 (human IgG) levels in plasma. (C) AL002 (human IgG) brain concentration in ng/ml was converted to ng/mg protein assuming a brain volume of 0.5 ml and a protein content of 38 mg. Using this calculation, we observed that ∼0.11% of AL002 penetrated in brain across all time points and animals. The terminal half-life in TREM2-Bac-Tg mice ranged from 1 to 1.8 d. Data are presented as mean ± SD. (D and E) PK parameters for plasma and brain were calculated using WinNonlin. n = 4 for each time point. AUClast, area under the curve concentration; Cmax, maximum plasma concentration; HL_Lambda_z (days), half-life; Tmax (days), time to maximum plasma concentration. (F) Functional EC50 of AL002. Viability of primary hTREM2+ macrophages from two distinct donors was measured by ATP assay after exposure of cells to different concentrations of AL002. The EC50 value of AL002 spans 0.36–0.47 nM (∼60 ng/ml).
Figure S2. AL002 pharmacokinetics. (A) Timeline of pharmacokinetics (PK) study of AL002 in TREM2-Bac-Tg mice. A single dose of AL002 was administered on day 0 at 5, 20, and 60 mg/kg. Different mouse cohorts were sacrificed on days 1, 2, 4, 8, 14, and 21, and plasma and brain samples were collected for measurement of antibody levels. (B) AL002 (human IgG) levels in plasma. (C) AL002 (human IgG) brain concentration in ng/ml was converted to ng/mg protein assuming a brain volume of 0.5 ml and a protein content of 38 mg. Using this calculation, we observed that ∼0.11% of AL002 penetrated in brain across all time points and animals. The terminal half-life in TREM2-Bac-Tg mice ranged from 1 to 1.8 d. Data are presented as mean ± SD. (D and E) PK parameters for plasma and brain were calculated using WinNonlin. n = 4 for each time point. AUClast, area under the curve concentration; Cmax, maximum plasma concentration; HL_Lambda_z (days), half-life; Tmax (days), time to maximum plasma concentration. (F) Functional EC50 of AL002. Viability of primary hTREM2+ macrophages from two distinct donors was measured by ATP assay after exposure of cells to different concentrations of AL002. The EC50 value of AL002 spans 0.36–0.47 nM (∼60 ng/ml).CC BY-NC-SA · PubMed Central
Figure 2. scRNA-seq analysis of microglia in treated mice. (A) Schematic of the scRNA-seq experiment. (B) UMAP of microglia subclustered from all Cd45+ cells. HM1-5, homeostatic microglia; TM, transitioning microglia; IRM, interferon-response microglia; PM1-2, proliferating microglia; SM, S-phase microglia. (C) Gene expression heatmap for clusters defined as microglia. Genes shown are the top gene markers for each cluster defined by Wilcoxon rank-sum test. The number of cells per cluster is denoted above the cluster label. (D) Mean normalized expression of key signature genes across clusters. Error bars represent SEM from all cells within the cluster. (E) Normalized expression of key signature genes on UMAP.
Figure 2. scRNA-seq analysis of microglia in treated mice. (A) Schematic of the scRNA-seq experiment. (B) UMAP of microglia subclustered from all Cd45+ cells. HM1-5, homeostatic microglia; TM, transitioning microglia; IRM, interferon-response microglia; PM1-2, proliferating microglia; SM, S-phase microglia. (C) Gene expression heatmap for clusters defined as microglia. Genes shown are the top gene markers for each cluster defined by Wilcoxon rank-sum test. The number of cells per cluster is denoted above the cluster label. (D) Mean normalized expression of key signature genes across clusters. Error bars represent SEM from all cells within the cluster. (E) Normalized expression of key signature genes on UMAP.CC BY-NC-SA · PubMed Central
Figure S3. scRNA-seq of Cd45+ cells from brains of AL002c- and IgG-treated mice. (A) UMAP of all Cd45+ cells. Clusters were annotated using previously identified gene markers: HM, homeostatic microglia; IRM, interferon-response microglia; NK, natural killer cells; CP BAM, choroid plexus BAMs. (B) Gene expression heatmap for all Cd45+ clusters. Genes shown are the top gene markers for each cluster defined by a Wilcoxon rank-sum test. The number of cells per cluster is denoted above the cluster label.
Figure S3. scRNA-seq of Cd45+ cells from brains of AL002c- and IgG-treated mice. (A) UMAP of all Cd45+ cells. Clusters were annotated using previously identified gene markers: HM, homeostatic microglia; IRM, interferon-response microglia; NK, natural killer cells; CP BAM, choroid plexus BAMs. (B) Gene expression heatmap for all Cd45+ clusters. Genes shown are the top gene markers for each cluster defined by a Wilcoxon rank-sum test. The number of cells per cluster is denoted above the cluster label.CC BY-NC-SA · PubMed Central
Figure 3. Impact of antibody treatment and TREM2 variants on microglia clusters. (A) Comparison of genes’ mean cluster z-scores from microglial clusters (x axis) to gene signatures (y axis) taken from Sala Frigerio et al. (2019) and Keren-Shaul et al. (2017). (B) Fraction of all cells belonging to the microglia clusters or other Cd45+ cells. (C) Fraction of cells in each cluster for each antibody treatment (adjusted for number of cells belonging to each mouse). (D) Identical to C except for combined genotype and antibody categories. (E) Identical to C except for mice.
Figure 3. Impact of antibody treatment and TREM2 variants on microglia clusters. (A) Comparison of genes’ mean cluster z-scores from microglial clusters (x axis) to gene signatures (y axis) taken from Sala Frigerio et al. (2019) and Keren-Shaul et al. (2017). (B) Fraction of all cells belonging to the microglia clusters or other Cd45+ cells. (C) Fraction of cells in each cluster for each antibody treatment (adjusted for number of cells belonging to each mouse). (D) Identical to C except for combined genotype and antibody categories. (E) Identical to C except for mice.CC BY-NC-SA · PubMed Central
Figure 4. AL002c expands metabolically active and proliferating microglia. (A and B) Bar plot of the percentage of cells in cluster 7 (**, P = 6.4 × 10−3; A) and cluster 9 (**, P = 3.4 × 10−3; B) on a per-mouse basis. Data are presented as mean ± SEM. (C) Wilcoxon rank-sum tests comparing cluster 7 to cluster 1 (homeostatic microglia). Genes above the −log(FDR adjusted P values) cutoff of 100 are annotated. (D) Identical to C except comparing cluster 9 to all other clusters. FC, fold-change. (E) Venn diagram showing the number of shared DEGs found with Wilcoxon rank-sum test for cluster 7 and cluster 9. Cluster 7’s DEGs were computed by comparing cluster 7 to cluster 1. Cluster 9’s DEGs were computed by comparing cluster 9 to all other clusters. (F and G) GO term analysis for positive fold-change DEGs in cluster 7 and cluster 9. (H) Mean normalized gene expression grouped by TREM2 variant and antibody treatment in all microglia.
Figure 4. AL002c expands metabolically active and proliferating microglia. (A and B) Bar plot of the percentage of cells in cluster 7 (**, P = 6.4 × 10−3; A) and cluster 9 (**, P = 3.4 × 10−3; B) on a per-mouse basis. Data are presented as mean ± SEM. (C) Wilcoxon rank-sum tests comparing cluster 7 to cluster 1 (homeostatic microglia). Genes above the −log(FDR adjusted P values) cutoff of 100 are annotated. (D) Identical to C except comparing cluster 9 to all other clusters. FC, fold-change. (E) Venn diagram showing the number of shared DEGs found with Wilcoxon rank-sum test for cluster 7 and cluster 9. Cluster 7’s DEGs were computed by comparing cluster 7 to cluster 1. Cluster 9’s DEGs were computed by comparing cluster 9 to all other clusters. (F and G) GO term analysis for positive fold-change DEGs in cluster 7 and cluster 9. (H) Mean normalized gene expression grouped by TREM2 variant and antibody treatment in all microglia.CC BY-NC-SA · PubMed Central
Figure 5. AL002c reduces soluble Aβ load and modifies the conformation of Aβ plaques. (A) Timeline of AL002c treatment in CV-KO-5XFAD or R47H-KO-5XFAD mice. 5-mo-old mice were injected i.p. with AL002c at 30 mg/kg weekly for 12 wk. Littermates were administered the same concentration of IgG as a control group. The behavioral test was performed after the 10th injection. Brains were harvested within 48 h after the last antibody injection. (B) AL002c concentrations in the cerebellum at the end of chronic treatment. To capture AL002c, brain lysates from AL002c- or IgG-treated mice were incubated with sTREM2 immobilized on plastic, followed by a secondary antibody. Only brain lysates containing AL002c but not control IgG test positive in this assay. (C) Representative confocal images from the cortex of CV-KO-5XFAD mice treated with AL002c stained with 6E10 (red) and methoxy-X04 (green), displaying three different forms of Aβ plaques. Red, green, and yellow arrowheads indicate filamentous, inert, and compact plaques, respectively. Bar = 100 µm. (D–F) Percentages of filamentous, inert, and compact plaques in each treatment group of mice. A total of 1,604 plaques were analyzed. CV-KO-5XFAD, AL002c, n = 6; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6. Each symbol represents data of one mouse. *, P < 0.05; **, P < 0.01 by two-way ANOVA. Although the overall effect of AL002c was significant across the CV and R47H genotypes in D and E, the AL002c effect was greater in the CV than the R47H genotype. Accordingly, in pairwise comparisons, AL002c treatment was significant in the CV but not the R47H genotype (P = 0.0066 and 0.1002 for D; P = 0.00257 and 0.3275 for E; from pairwise comparison of the fitted least square mean from the linear model). No significant interaction between antibody treatment and genotype was found. Data are presented as mean ± SEM and depict one experiment representative of three independent experiments.
Figure 5. AL002c reduces soluble Aβ load and modifies the conformation of Aβ plaques. (A) Timeline of AL002c treatment in CV-KO-5XFAD or R47H-KO-5XFAD mice. 5-mo-old mice were injected i.p. with AL002c at 30 mg/kg weekly for 12 wk. Littermates were administered the same concentration of IgG as a control group. The behavioral test was performed after the 10th injection. Brains were harvested within 48 h after the last antibody injection. (B) AL002c concentrations in the cerebellum at the end of chronic treatment. To capture AL002c, brain lysates from AL002c- or IgG-treated mice were incubated with sTREM2 immobilized on plastic, followed by a secondary antibody. Only brain lysates containing AL002c but not control IgG test positive in this assay. (C) Representative confocal images from the cortex of CV-KO-5XFAD mice treated with AL002c stained with 6E10 (red) and methoxy-X04 (green), displaying three different forms of Aβ plaques. Red, green, and yellow arrowheads indicate filamentous, inert, and compact plaques, respectively. Bar = 100 µm. (D–F) Percentages of filamentous, inert, and compact plaques in each treatment group of mice. A total of 1,604 plaques were analyzed. CV-KO-5XFAD, AL002c, n = 6; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6. Each symbol represents data of one mouse. *, P < 0.05; **, P < 0.01 by two-way ANOVA. Although the overall effect of AL002c was significant across the CV and R47H genotypes in D and E, the AL002c effect was greater in the CV than the R47H genotype. Accordingly, in pairwise comparisons, AL002c treatment was significant in the CV but not the R47H genotype (P = 0.0066 and 0.1002 for D; P = 0.00257 and 0.3275 for E; from pairwise comparison of the fitted least square mean from the linear model). No significant interaction between antibody treatment and genotype was found. Data are presented as mean ± SEM and depict one experiment representative of three independent experiments.CC BY-NC-SA · PubMed Central
Figure S4. Impact of AL002c treatment on total Aβ load. (A) Quantification of methoxy-X04+ area coverage in the cortex (Ctx) and hippocampus (HC) of treated mice. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. (B) Volume of individual methoxy-X04+ Aβ plaques in the cortex of indicated treatment groups. The volume of ∼1,000 plaques per condition was determined by Imaris. (C–F) PBS-soluble and PBS-insoluble guanidine-soluble fractions of hippocampus were assessed for Aβ1–40 (C and E) and Aβ1–42 (D and F) by MSD. Values for PBS-soluble Aβ1–40 were below the limit of detection in some samples. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. No differences were detected for Aβ1–40 or Aβ1–42 in PBS-insoluble guanidine-soluble fractions of cortices among treatment groups (not depicted). PBS-soluble fractions of cortices showed no detectable Aβ1–40 or Aβ1–42 by MSD. *, P < 0.05; **, P < 0.01 by two-way ANOVA. Data are presented as mean ± SEM.
Figure S4. Impact of AL002c treatment on total Aβ load. (A) Quantification of methoxy-X04+ area coverage in the cortex (Ctx) and hippocampus (HC) of treated mice. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. (B) Volume of individual methoxy-X04+ Aβ plaques in the cortex of indicated treatment groups. The volume of ∼1,000 plaques per condition was determined by Imaris. (C–F) PBS-soluble and PBS-insoluble guanidine-soluble fractions of hippocampus were assessed for Aβ1–40 (C and E) and Aβ1–42 (D and F) by MSD. Values for PBS-soluble Aβ1–40 were below the limit of detection in some samples. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. No differences were detected for Aβ1–40 or Aβ1–42 in PBS-insoluble guanidine-soluble fractions of cortices among treatment groups (not depicted). PBS-soluble fractions of cortices showed no detectable Aβ1–40 or Aβ1–42 by MSD. *, P < 0.05; **, P < 0.01 by two-way ANOVA. Data are presented as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 6. AL002c ameliorates neuronal damage and impacts anxiety-like traits. (A) Representative confocal images from the cortex of indicated groups of mice, showing methoxy-X04-labeled Aβ plaques (blue) and surrounding N terminus-APP+ neurites (red). Bars = 100 µm; insets, 25 µm. (B–D) Quantification of number (B), coverage (C), and volume (D) of dystrophic neurites per plaque in the indicated groups of mice. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. The effect of AL002c was significant across CV and R47H genotypes: **, P < 0.01 by two-way ANOVA. In C and D, the effect of AL002c was also independently significant in the CV and R47H genotypes in pairwise comparisons (P = 0.0293 and 0.019 for C; P = 0.0371 and 0.0409 for D; from pairwise comparison of the fitted least square mean from the linear model). (E–H) Anxiety-like traits in mice behavior were evaluated by EPM and are presented as total entries into open arms (E), distance in open arms (F), total distance (G), and total immobile time (H). (I and J) AL002c treatment does not affect general locomotor activities. Total ambulations and time at rest were quantified over a 60-min period in transparent enclosures. CV-KO-5XFAD, AL002c, n = 6; CV-KO-5XFAD, IgG, n = 6; R47H-KO-5XFAD, AL002c, n = 13; R47H-KO-5XFAD, IgG, n = 7. Each symbol represents data of one mouse. *, P < 0.05; **, P < 0.01 by two-way ANOVA. No significant interaction between antibody treatment and genotype was found. Data are presented as mean ± SEM.
Figure 6. AL002c ameliorates neuronal damage and impacts anxiety-like traits. (A) Representative confocal images from the cortex of indicated groups of mice, showing methoxy-X04-labeled Aβ plaques (blue) and surrounding N terminus-APP+ neurites (red). Bars = 100 µm; insets, 25 µm. (B–D) Quantification of number (B), coverage (C), and volume (D) of dystrophic neurites per plaque in the indicated groups of mice. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. The effect of AL002c was significant across CV and R47H genotypes: **, P < 0.01 by two-way ANOVA. In C and D, the effect of AL002c was also independently significant in the CV and R47H genotypes in pairwise comparisons (P = 0.0293 and 0.019 for C; P = 0.0371 and 0.0409 for D; from pairwise comparison of the fitted least square mean from the linear model). (E–H) Anxiety-like traits in mice behavior were evaluated by EPM and are presented as total entries into open arms (E), distance in open arms (F), total distance (G), and total immobile time (H). (I and J) AL002c treatment does not affect general locomotor activities. Total ambulations and time at rest were quantified over a 60-min period in transparent enclosures. CV-KO-5XFAD, AL002c, n = 6; CV-KO-5XFAD, IgG, n = 6; R47H-KO-5XFAD, AL002c, n = 13; R47H-KO-5XFAD, IgG, n = 7. Each symbol represents data of one mouse. *, P < 0.05; **, P < 0.01 by two-way ANOVA. No significant interaction between antibody treatment and genotype was found. Data are presented as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure S5. Impact of AL002c treatment on microglia clustering around plaques and Spp1 production (A) Representative confocal images from the hippocampus of indicated groups of mice, showing Iba1+ microglia (green), TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar, 100 µm. (B and C) Quantification of Iba1+ area coverage in the cortex (Ctx) and hippocampus (HC) of treated mice (CV-KO-5XFAD, AL002c, n = 7; CV-KO-5XFAD, IgG, n = 5; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Data are presented as mean ± SEM. (D) Representative confocal images from the cortex of the indicated groups of mice, showing Iba1+ (green) microglia, TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar = 50 µm. CV-KO-5XFAD treatment group, n = 7; R47H-KO-5XFAD treatment group, n = 6. (E and F) Quantification of the density of microglia within a 15- or 30-µm shell around plaque surfaces within cortex or hippocampus. The figure depicts one experiment representative of two biological replicates. *, P < 0.05 by two-way ANOVA, showing significant difference for interaction between antibody treatment and genotype. Data are presented as mean ± SEM. (G) 5-mo-old 5XFAD and hTREM2-Bac-Tg × 5XFAD mice were injected i.p. with AL002c or IgG as control (n = 10) at 60 mg/kg weekly for 12 wk. Littermates were administered the same concentration of IgG as a control group. SPP1 was measured by ELISA in brain lysates of treated mice. Each symbol represents data of one mouse. ****, P < 0.0001 by one-way ANOVA. Data are presented as mean ± SEM.
Figure S5. Impact of AL002c treatment on microglia clustering around plaques and Spp1 production (A) Representative confocal images from the hippocampus of indicated groups of mice, showing Iba1+ microglia (green), TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar, 100 µm. (B and C) Quantification of Iba1+ area coverage in the cortex (Ctx) and hippocampus (HC) of treated mice (CV-KO-5XFAD, AL002c, n = 7; CV-KO-5XFAD, IgG, n = 5; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Data are presented as mean ± SEM. (D) Representative confocal images from the cortex of the indicated groups of mice, showing Iba1+ (green) microglia, TO-PRO3-stained nuclei (red), and methoxy-X04 labeled Aβ plaques (blue). Bar = 50 µm. CV-KO-5XFAD treatment group, n = 7; R47H-KO-5XFAD treatment group, n = 6. (E and F) Quantification of the density of microglia within a 15- or 30-µm shell around plaque surfaces within cortex or hippocampus. The figure depicts one experiment representative of two biological replicates. *, P < 0.05 by two-way ANOVA, showing significant difference for interaction between antibody treatment and genotype. Data are presented as mean ± SEM. (G) 5-mo-old 5XFAD and hTREM2-Bac-Tg × 5XFAD mice were injected i.p. with AL002c or IgG as control (n = 10) at 60 mg/kg weekly for 12 wk. Littermates were administered the same concentration of IgG as a control group. SPP1 was measured by ELISA in brain lysates of treated mice. Each symbol represents data of one mouse. ****, P < 0.0001 by one-way ANOVA. Data are presented as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 7. Impact of AL002c on microglial responses to Aβ. (A) Morphology of microglia associated with plaques (blue) highlighting the shape of cell bodies (red) and primary processes (cyan) in the cortex (Ctx) of indicated groups of mice. Bar = 20 µm. (B and C) Cell body volume (B) and average length of primary processes (C) of plaque-associated microglia were measured by Imaris using z-stack confocal images. Images of total 21 or 18 plaques with >180 microglia per treatment group were analyzed. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. **, P < 0.01; ***, P < 0.001 by two-way ANOVA. HC, hippocampus. (D) Representative confocal images by three-dimensional reconstruction of the cortex of indicated groups of mice, depicting engulfed Aβ (red) by CD68+ phagosome (green). Bar = 25 µm. (E) Quantification of the ratio of Aβ colocalized with CD68 over total Aβ volume. n = 4 for each treatment group. Each symbol represents data of one mouse. *, P < 0.05 by two-way ANOVA. A significant interaction was detected between antibody treatment and genotype in C and E, such that the effect of the antibody treatment is greater in the CV-KO-5XFAD than the R47H-KO-5XFAD genotype. Data are presented as mean ± SEM. (F) Representative confocal images of the cortex of the indicated groups of mice, depicting Aβ plaques (methoxy-X04, blue), Iba1 (red), and Spp1 (green). Bar = 100 µm. (G) Quantification of the percentage of Spp1+ pixels within Iba1+ pixels in the indicated genotypes of mice (CV-KO-5XFAD, AL002c, n = 7; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Each symbol represents data of one mouse. **, P < 0.01 by two-way ANOVA. No interaction between antibody treatment and genotype was detected. Data are presented as mean ± SEM.
Figure 7. Impact of AL002c on microglial responses to Aβ. (A) Morphology of microglia associated with plaques (blue) highlighting the shape of cell bodies (red) and primary processes (cyan) in the cortex (Ctx) of indicated groups of mice. Bar = 20 µm. (B and C) Cell body volume (B) and average length of primary processes (C) of plaque-associated microglia were measured by Imaris using z-stack confocal images. Images of total 21 or 18 plaques with >180 microglia per treatment group were analyzed. Each CV-KO-5XFAD treatment group, n = 7; each R47H-KO-5XFAD treatment group, n = 6. **, P < 0.01; ***, P < 0.001 by two-way ANOVA. HC, hippocampus. (D) Representative confocal images by three-dimensional reconstruction of the cortex of indicated groups of mice, depicting engulfed Aβ (red) by CD68+ phagosome (green). Bar = 25 µm. (E) Quantification of the ratio of Aβ colocalized with CD68 over total Aβ volume. n = 4 for each treatment group. Each symbol represents data of one mouse. *, P < 0.05 by two-way ANOVA. A significant interaction was detected between antibody treatment and genotype in C and E, such that the effect of the antibody treatment is greater in the CV-KO-5XFAD than the R47H-KO-5XFAD genotype. Data are presented as mean ± SEM. (F) Representative confocal images of the cortex of the indicated groups of mice, depicting Aβ plaques (methoxy-X04, blue), Iba1 (red), and Spp1 (green). Bar = 100 µm. (G) Quantification of the percentage of Spp1+ pixels within Iba1+ pixels in the indicated genotypes of mice (CV-KO-5XFAD, AL002c, n = 7; CV-KO-5XFAD, IgG, n = 7; R47H-KO-5XFAD, AL002c, n = 6; R47H-KO-5XFAD, IgG, n = 6). Each symbol represents data of one mouse. **, P < 0.01 by two-way ANOVA. No interaction between antibody treatment and genotype was detected. Data are presented as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 8. Biomarkers in first-in-human phase I clinical trial. (A and B) Administration of a single dose of AL002 caused a dose-dependent decrease in cerebrospinal fluid of sTREM2 (A) from baseline within 2 d that was paralleled by an increase in sCSF-1R concentration (B). P = 0.0001 for 6 mg/kg and P < 0.0001 for all other doses vs. pooled placebo control (A) and P = 0.026 at 60 mg/kg vs. pooled placebo (B) by mixed-model repeated measures analysis adjusted for multiplicities using Dunnett's test. Data are presented as mean ± SD; cohort n = 6 (placebo, 6 mg/kg, 15 mg/kg, 30 mg/kg) and 5 (45 mg/kg, 60 mg/kg).
Figure 8. Biomarkers in first-in-human phase I clinical trial. (A and B) Administration of a single dose of AL002 caused a dose-dependent decrease in cerebrospinal fluid of sTREM2 (A) from baseline within 2 d that was paralleled by an increase in sCSF-1R concentration (B). P = 0.0001 for 6 mg/kg and P < 0.0001 for all other doses vs. pooled placebo control (A) and P = 0.026 at 60 mg/kg vs. pooled placebo (B) by mixed-model repeated measures analysis adjusted for multiplicities using Dunnett's test. Data are presented as mean ± SD; cohort n = 6 (placebo, 6 mg/kg, 15 mg/kg, 30 mg/kg) and 5 (45 mg/kg, 60 mg/kg).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 579

Metadata

Authors
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M.
Affiliations
  • Washington University in St. Louis (US)
  • Alector (United States) (US)
Corresponding author
  • Schwabe, Tina
  • Colonna, Marco
Venue
Journal of Experimental Medicine
Published
2020-06-24
Volume
217
Issue
9
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3037497912
Cited by
549
References
41
Citations by year
2026: 106 · 2025: 115 · 2024: 101 · 2023: 93 · 2022: 64 · 2021: 52 · 2020: 18
FWCI
21.97
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (RF1AG05148501, R21 AG059176, RF1 AG059082)
  • Cure Alzheimer’s Fund
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
TREM2, Alzheimer's disease, microglial proliferation, amyloid plaques, microglial inflammation, transgenic mouse model, single-cell RNA sequencing, cerebrospinal fluid biomarkers, immunotherapy
MeSH terms
Alzheimer Disease, Animals, Antibodies, Monoclonal, Anxiety, Blood-Brain Barrier, Disease Models, Animal, Humans, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Transgenic, Protein Conformation, Receptors, Immunologic, Solubility, Signal Transduction, Biomarkers, Amyloid beta-Peptides, Neurites, Microglia, Cell Proliferation, Osteopontin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. https://app.cochat.ai/papers/10.1084/jem.20200785
The paper
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M. (2020). Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20200785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.